Superworth

Immunovant EPS IMVT

Diluted earnings per share by quarter and over the last twelve months, from 2018.

Last 12 months, to Jun 30, 2026
−$2.82
Latest quarter, Q1 FY27
−$0.75
Fiscal year 2026
−$2.78

Immunovant's earnings per share was −$2.82 over the twelve months to Jun 30, 2026.

In its latest quarter, Q1 FY27, it was −$0.75.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2026−$2.78n/a
FY2025−$2.74n/a
FY2024−$1.90n/a
FY2023−$1.71n/a
FY2022−$1.42n/a
FY2021−$1.24n/a
FY2020−$1.56n/a
FY2019n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q1 FY27−$0.75n/a−$2.82
Q4 FY26−$0.73n/a−$2.78
Q3 FY26−$0.61n/a−$2.69
Q2 FY26−$0.73n/a−$2.84
Q1 FY26−$0.71n/a−$2.85
Q4 FY25−$0.64n/a−$2.74
Q3 FY25−$0.76n/a−$2.62
Q2 FY25−$0.74n/a−$2.22
Q1 FY25−$0.60n/a−$1.93
Q4 FY24−$0.52n/a−$1.90
Q3 FY24−$0.36n/a−$1.84
Q2 FY24−$0.45n/a−$1.97

Against its peers

Companies in Biotechnology nearest Immunovant's size, closest first, today.

CompanyEPS, 12 monthsGrowth
IMVTImmunovant−$2.82
KRYSKrystal Biotech$7.98+62% a year
RGENRepligen$0.73
TECHBIO-TECHNE$1.15+150% a year
HALOHalozyme Therapeutics$3.35−23% a year
ADMAAdma Biologics$0.70−18% a year
NBIXNeurocrine Biosciences$6.82+102% a year
VCELVericel$0.46+283% a year
EXELExelixis$3.18+53% a year
INCYIncyte$7.85+78% a year
UTHRUnited Therapeutics$27.95+9% a year
Peer median$3.27

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Immunovant

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.